NIKKEI 225
31,752.44 -120.08 (-0.38%) HANG SENG
17,837.16 +464.13 (+2.67%) CRUDE OIL
91.76 +0.05 (+0.05%) GOLD FUTURES
1,881.50 +2.90 (+0.15%) DOW
33,666.34 +116.07 (+0.35%) Bitcoin GBP
22,069.36 +461.47 (+2.14%)
BEAM Jan 2024 30.000 put
| Previous close | 7.50 |
| Open | 7.50 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 30.00 |
| Expiry date | 2024-01-19 |
| Day's range | 7.50 - 7.50 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Motley Fool2 Magnificent Growth Stocks to Buy On the Dip
Despite a sizzling start to the year, growth stocks have suddenly found themselves on the outs with investors. Concerns about the global economy, persistently high interest rates, and stubborn levels of inflation have weighed heavily on pure-play growth stocks in the second half of the year. Biotechnology stocks have taken a particularly hard hit over this period.
Motley Fool3 Stocks Cathie Wood Is Buying That Should Be on Your List, Too
Warren Buffett has been a net seller of stocks in recent months, but it's a different story for Cathie Wood. If you're an aggressive investor, here are three stocks that Wood is buying that should be on your list, too. Wood's flagship Ark Innovation ETF added to its existing position in Beam Therapeutics (NASDAQ: BEAM) over the last several weeks.
Motley FoolThis Cathie Wood Stock Is Down 40% in 2023. Here's Why She's Still Buying It.
Beam Therapeutics' (NASDAQ: BEAM) stock has fallen by 40% this year so far, but that hasn't stopped portfolio manager Cathie Wood's ARK Genomic Revolution ETF from loading up on its shares. Now, the stock accounts for nearly 2% of the ARK Invest portfolio of exchange-traded funds (ETFs). Cathie Wood is unlikely to harbor any illusions about Beam Therapeutics as it exists today.
